Related Experiment Video
Updated: May 15, 2026
07:02
In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
Published on: August 23, 2019
Secretome proteins as candidate biomarkers for aggressive thyroid carcinomas
Seham Chaker1, Lawrence Kashat, Sebastien Voisin
1Alex and Simona Shnaider Laboratory in Molecular Oncology, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, ON, Canada.
Proteomics
|January 16, 2013
Summary
Proteomics identified potential biomarkers for thyroid carcinoma (TC) aggressiveness. Elevated ALCAM and AXL in patient sera correlated with aggressive tumors and metastasis, showing promise for early detection.
Area of Science:
- Molecular Biology
- Oncology
- Proteomics
- Bioinformatics
Background:
- Thyroid carcinoma (TC) poses a significant health challenge, with tumor aggressiveness varying widely.
- Identifying reliable biomarkers for TC aggressiveness is crucial for effective patient management and treatment strategies.
- Current diagnostic methods may not fully capture the nuances of tumor behavior and metastatic potential.
Purpose of the Study:
- To identify novel protein biomarkers indicative of thyroid carcinoma (TC) tumor aggressiveness using a proteomics and bioinformatics approach.
- To evaluate the diagnostic and prognostic potential of selected proteins in patient sera and tissues.
- To correlate protein expression levels with clinical parameters such as tumor stage and lymph node metastasis.
Main Methods:
- Proteomic analysis of secretomes from nonaggressive and aggressive TC cell lines.
- Bioinformatic analysis to identify differentially expressed proteins.
- Validation of candidate biomarkers (ALCAM, AXL, amyloid beta A4, etc.) in TC patient sera and tissues using established methods.
- Statistical analysis to correlate protein levels with clinical outcomes.
Main Results:
- Nine proteins were selected as potential biomarkers, including ALCAM, AXL, and others.
- Increased serum levels of ALCAM were significantly associated with tumor aggressiveness (p = 0.04) and lymph node metastasis (p = 0.018).
- Elevated serum AXL levels correlated with extrathyroidal extension (p = 0.027).
- Differential expression of several proteins (amyloid beta A4, AXL, etc.) was observed in TC tissues compared to benign nodules.
- Decreased nuclear AXL expression demonstrated high accuracy (90% specificity, 100% sensitivity, AUC = 0.995) in detecting malignancy.
Conclusions:
- The study identified several proteins with potential as serum and/or tissue-based biomarkers for thyroid carcinoma aggressiveness.
- ALCAM and AXL show particular promise for non-invasive detection and prognostication of TC.
- Further validation in larger patient cohorts is warranted to confirm the clinical utility of these biomarkers.
